LPIN1 and rhabdomyolysis: Factors that lead to changes in glycolysis, glycogen breakdown, fat oxidation, and mitochondrial respiration can impair skeletal muscle function, resulting in severe myopathies and rhabdomyolysis.[13] Various studies have shown that lipid-lowering medications interfere with several pathways of muscle cell energy metabolism and affect muscle lipoprotein lipase activity.[11] Childhood rhabdomyolysis has a relatively common genetic origin in mutations of the LPIN1 gene.